Genenta Science SPA (FRA:K5F) Other Stockholders Equity: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:K5F Genenta Science SPA FRA:K5F
38 GF Score
Price €1.14
! 4 Warning Signs
View Full Analysis

What is Genenta Science SPA Other Stockholders Equity?

Genenta Science SPA FRA:K5F +3.64% 38 Other Stockholders Equity is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:K5F with a GF Score™ of 38/100. The stock has 4 warning signs investors should review.

Genenta Science SPA's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €0.00 Mil.

Genenta Science SPA's quarterly Other Stockholders Equity declined from Dec. 2024 (€0.00 Mil) to Jun. 2025 (€-0.00 Mil) but then increased from Jun. 2025 (€-0.00 Mil) to Dec. 2025 (€0.00 Mil).

Genenta Science SPA's annual Other Stockholders Equity increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Genenta Science SPA Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Genenta Science SPA's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genenta Science SPA Other Stockholders Equity Chart

Genenta Science SPA Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial -0.00 0.00 0.00 0.00 0.00

Genenta Science SPA Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
FRA:K5F
38GF Score
Genenta Science SPA FRA:K5F
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genenta Science SPA Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.00 Mil mean?
Genenta Science SPA (FRA:K5F) has a Other Stockholders Equity of €0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Genenta Science SPA and its competitors.
Is Genenta Science SPA's Other Stockholders Equity too high?
Genenta Science SPA's current Other Stockholders Equity is €0.00 Mil. Overall, Genenta Science SPA has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Genenta Science SPA's Other Stockholders Equity compare to VRTX and REGN?
Genenta Science SPA's Other Stockholders Equity of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Genenta Science SPA and its competitors. Genenta Science SPA's current Other Stockholders Equity is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genenta Science SPA stock overvalued right now?
Genenta Science SPA (FRA:K5F) has a current Other Stockholders Equity of €0.00 Mil. The current Other Stockholders Equity is €0.00 Mil. Genenta Science SPA's overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Genenta Science SPA (FRA:K5F), the current Other Stockholders Equity is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genenta Science SPA Business Description

Other Exchanges GNTA:USA
Address Via dell’Annunciata No. 31, Milan, ITA, 20121
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
38GF Score

Get the complete analysis for FRA:K5F

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.14
Price